Pharma stocks slip as Trump renews threats of 'major' pharmaceutical tariff
While the omission of pharmaceuticals from President Donald Trump’s much-anticipated reciprocal tariffs gave the industry a momentary reprieve, renewed threats of drug duties—which have pressured scores of health stocks—suggest any relief is likely short-lived.
While the omission of pharmaceuticals from President Donald Trump’s much-anticipated reciprocal tariffs gave the industry a momentary reprieve, renewed threats of drug duties—which have pressured scores of health stocks—suggest any relief is likely short-lived.
